Core Insights - NeuroOne Medical Technologies Corporation is addressing the needs of epilepsy patients who do not respond to traditional antiseizure medications, which affects approximately one million individuals in the U.S. alone [2][3] Company Overview - NeuroOne has developed the OneRF™ ablation system, the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously [4] - The OneRF™ system includes an electrode for monitoring brain activity, a temperature probe, and a radio frequency heat generation system, ensuring safe ablation temperatures [4][5] Innovation and Impact - The OneRF™ system allows for a single hospitalization for both electrode placement and ablation, streamlining the treatment process compared to previous methods that required multiple invasive surgeries [5][6] - A case study highlighted a teenage patient who experienced significant seizure reduction after using the OneRF™ system, demonstrating its potential effectiveness [6] Industry Context - Approximately 50 million people worldwide are affected by epilepsy, with over three million diagnosed in the U.S. [2] - NeuroOne is also exploring applications for other neurological disorders, including Parkinson's disease and chronic pain, which may improve patient outcomes and reduce procedural costs [8][9]
NeuroOne CEO Joins Today's Marketplace To Discuss The Latest Treatments for Epilepsy